CDKN2A and atherosclerosis: In addition, traditional markers of cell senescence such as p16INK4A have significant limitations in identifying and removing SC in atherosclerosis, suggesting that senescence studies in atherosclerosis and new senolytic drugs require more specific and lineage-restricted markers before ascribing their effects entirely to senolysis [237].